🟢 Cybin is trading 5% up in pre-market after four HLP003 presentations at Psych Congress 2026

Cybin is trading at $14.37, up 5.21% after releasing four HLP003 research presentations at Psych Congress 2026.

• Analyses included 12-month efficacy findings from a Phase 1/2a study and an overview of the ongoing Phase 3 PARADIGM program for adjunctive major depressive disorder.
• Cybin gained 10.43% on September 21 following the announcement.
• Phase 3 HLP003 topline results remain expected during Q4 2026, supporting continued enthusiasm around the psychedelic-treatment pipeline.